This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

SKAMo-2: the Real-life Test of Continuous Photoacoustic Signal by Neogly in Patients With Type I Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06035367
Recruitment Status : Recruiting
First Posted : September 13, 2023
Last Update Posted : September 13, 2023
Sponsor:
Information provided by (Responsible Party):
Eclypia

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Diabetes is one of the very common and chronic diseases in the present world, which affects children and adults. Diabetes is characterized by hyperglycemia. Hence, diabetic patients need to precisely monitor their blood sugar level regularly a few times a day. Currently, the solutions for self-monitoring blood glucose are invasive (finger prick method, continuous glucose monitoring (CGM) using microneedle).The fully non-invasive CGM approaches still are in high demand.

The medical device is developed, ultimately, to continuously measure the blood glucose level from continuous in-vivo photoacoustic signal.

For this study, the goal is to check if the signal collected by the investigational device is relevant and exploitable in patients with type I diabetes.

The main task of participants is to wear the investigational device during one week.


Condition or disease Intervention/treatment Phase
Diabetes Device: Non-invasive continuous monitoring device to record photoacoustic signal Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: SKAMo-2: the Real-life Test of Continuous Photoacoustic Signal by Neogly in Patients With Type I Diabetes
Actual Study Start Date : July 6, 2023
Estimated Primary Completion Date : October 30, 2023
Estimated Study Completion Date : October 30, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Wearing the non-invasive continous monitoring device during one week to record photoacoustic signal
Wearing the non-invasive continous monitoring device during one week to record photoacoustic signal
 Device: Non-invasive continuous monitoring device to record photoacoustic signal

Neogly is in two parts, the measurement head, to be worn on the wrist and the power box, to be worn on the forearm or upper arm. The ribbon cable makes the connection between the two parts.

A handset is used to start/stop the device. The medical device record a continuous photoacoustic signal.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Value of absolute photoacoustic signal on the participant arm [ Time Frame: around one week (7 to 9 days) ]
    The first endpoint is evaluated by the value of photoacoustic signal on the participant arm. To check if if the photoacoustic data of the investigational device are relevant and exploitable. This signal should be above a given threshold, corresponding to an absolute photoacoustic value at least three times higher than this measured when the device is not worn.


Secondary Outcome Measures :
  1. assess the safety by the general clinical evaluation (normal, abnormal, abnormal not clinically significant) [ Time Frame: around one week (7 to 9 days) ]
    baseline (V1) and after the device wearing (V2)

  2. assess the safety by number/class of adverse events [ Time Frame: during one week (7 to 9 days) ]
    definitions of AE from European Medical Device Regulation 2017/745

  3. assess the tolerability of the investigational device by a usability questionnaire [ Time Frame: around one week (7 to 9 days) ]
    some questions with scales from 1 to 10 (no total score) and other questions with a free field to collect the user feedback about the size, appearance, comfort, operation of the device and the suggestions for device improvement


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with type I diabetes
  • male and female patients aged 18 to 50 years
  • wearing a FreeStyle Libre CGM and giving the access of collected data
  • using insulin pump or insulin pen and giving the access of collected data
  • willing to wear the investigational device continuously throughout the study (24h/24h)
  • affiliated with French Social Security
  • having signed the informed consent form

Exclusion Criteria:

  • any skin disease (inflammatory diseases of skin, cancer of skin, infectious diseases of skin, change in skin color...)
  • any serious disease that could interfere with the study
  • body mass index (BMI) > 30kg/m2
  • scars or tattoos on the upper side of the wrist wearing the investigational device
  • who may have an allergy to one of the material used in the device
  • who have magnetic resonance imagery (MRI), computed tomography (CT) scan or high frequency electrical heat (diathermy) treatment during the study
  • persons mentioned in articles L1121-5 to L1121-9 of the public health code (Pregnancy or Lactation ; Females with childbearing potential, defined as a premenopausal female and not using an effective form of birth control*; Person deprived of liberty by judicial order ; Person under guardianship or curatorship ; Minors ; Adults who are incapable or unable to give their consent ; Cross-over situations)
  • who would receive more than 4500 euros in compensation due to his or her participation in other research involving the human person in the 12 months preceding this study
  • who, in the judgment of the investigator, are likely to be non-compliant or uncooperative during the study, or unable to cooperate because of language problem, poor mental development
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06035367


Contacts
Layout table for location contacts
Contact: Eclypia 33476767383 contact@eclypia.com

Locations
Layout table for location information
France
CHU Grenoble Alpes Recruiting
Grenoble, France, 38043
Contact: Centre d'investigation clinique Centre d'investigation clinique    334.76.767.575    CIC@chu-grenoble.fr   
Principal Investigator: Pierre-Yves Pr BENHAMOU, principal investigator         
Sponsors and Collaborators
Eclypia
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Eclypia
ClinicalTrials.gov Identifier: NCT06035367    
Other Study ID Numbers: 2022-A02789-34
First Posted: September 13, 2023    Key Record Dates
Last Update Posted: September 13, 2023
Last Verified: September 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
 Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases